Inhibikase Therapeutics (IKT) Profit After Tax Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 91.31% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 90.66% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 59.34% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -50.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.23% |
| Mar 31, 2026 | -54.08% |
| Dec 31, 2025 | -43.84% |
| Sep 30, 2025 | -38.46% |
| Jun 30, 2025 | -28.81% |
| Mar 31, 2025 | -43.38% |
| Dec 31, 2024 | -34.01% |
| Sep 30, 2024 | -8.92% |
| Jun 30, 2024 | -23.45% |
| Mar 31, 2024 | -20.81% |
| Dec 31, 2023 | -51.23% |
| Sep 30, 2023 | -89.94% |
| Jun 30, 2023 | -139.26% |
| Mar 31, 2023 | -101.48% |